Medicus Pharma (NASDAQ:MDCX) Rating Lowered to Hold at Brookline Capital Markets

Medicus Pharma (NASDAQ:MDCX) was downgraded by stock analysts at Brookline Capital Markets from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, FinViz reports.

A number of other research analysts have also commented on MDCX. Alliance Global Partners reiterated a “buy” rating on shares of Medicus Pharma in a research note on Monday, September 14th. Wall Street Zen downgraded shares of Medicus Pharma from a “sell” rating to a “strong sell” rating in a research report on Sunday. Finally, Weiss Ratings upgraded Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $450.00.

Medicus Pharma Price Performance

MDCX stock traded down $0.12 during midday trading on Wednesday, reaching $1.71. 32,793 shares of the company were exchanged, compared to its average volume of 82,472. The business has a 50-day moving average price of $5.69 and a two-hundred day moving average price of $21.07. Medicus Pharma has a one year low of $1.68 and a one year high of $127.50. The firm has a market capitalization of $2.15 million, a price-to-earnings ratio of -0.02 and a beta of 0.80.

Medicus Pharma (NASDAQ:MDCX) last issued its quarterly earnings data on Friday, November 6th. The company reported ($11.64) earnings per share for the quarter, missing the consensus estimate of ($8.50) by ($3.14). As a group, analysts anticipate that Medicus Pharma will post -33.50 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Medicus Pharma

A number of institutional investors have recently modified their holdings of MDCX. Interchange Capital Partners LLC increased its position in Medicus Pharma by 33.9% during the third quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock worth $343,000 after acquiring an additional 538,039 shares during the period. Sterling Investment Advisors Ltd. acquired a new stake in Medicus Pharma in the 2nd quarter worth about $45,000. Finally, Private Advisor Group LLC acquired a new stake in Medicus Pharma in the 3rd quarter worth about $37,000.

Medicus Pharma Company Profile

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes. Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.